Key Drivers
- Strong Cash Flow
- Rising Leverage
- Negative Equity
AIAI Summary
BioCryst is increasingly a cash-generating commercial story thanks to ORLADEYO's growth, rising margins, and strong free cash flow, but the investment case still hinges on sustaining that momentum while navigating high debt, product concentration, and navenibart execution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Rising Leverage
- •Negative Equity
BCRX is generating strong margins and cash flow with improving liquidity, but the investment case is held back by rising debt and deeply negative equity.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Resistance Near $10.6
- •Choppy Recovery
BCRX is modestly higher over the last month, with buyers defending $8.8–$9.0 support, but the rally stalled near $10.6, leaving momentum improved yet unconfirmed.
Sharp rebound from $8.81 to $10.59, followed by a quick pullback from the $10.6 area
Sentiment & News
Key News Insights:
- •Earnings beat
- •Guidance raised
- •Investor interest
BioCryst delivered a strong Q2 beat with raised 2026 guidance, continued ORLADEYO momentum, and advancing navenibart execution, while investor interest and bullish sentiment around BCRX picked up.
The update is constructive for BCRX, signaling improving fundamentals and growing market attention that could support the stock near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings